Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review
Abstract Background Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a...
Celine Hoyek, Cody R. Eslinger, Angelo Pirozzi et al.
· BMC Cancer · 0 citations